Endo Inc. Company Description
Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals.
The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology.
Its products include XIAFLEX, a non-surgical treatment for Peyronie’s Disease for adult men with a collagen plaque and a penile curvature deformity; and Dupuytren’s Contracture for adult patients with an abnormal buildup of collagen in the fingers that limits or disables hand function.
This segment is also developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty.
The Sterile Injectable segment offers ADRENALIN, a non-selective alpha- and beta-adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; and VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
The Generic Pharmaceuticals segment provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays, as well as products that treat and manage a rage of medical conditions.
The International Pharmaceuticals segment sells a range of specialty pharmaceutical products primarily to customers in Canada.
Its principal products serve various therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health, oncology, and transplantation, as well as over-the-counter products.
The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,931 |
| CEO | Scott Hirsch |
Contact Details
Address: 1400 Atwater Drive Malvern, Delaware 19355 United States | |
| Phone | 484 216 0000 |
| Website | endo.com |
Stock Details
| Ticker Symbol | NDOI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott A. Hirsch | Interim Chief Executive Officer and Director |
| Mark T. Bradley | Executive Vice President and Chief Financial Officer |
| Matthew Joseph Maletta | Executive Vice President, Chief Legal Officer and Company Secretary |
| Patrick A. Barry | Executive Vice President and President of Global Commercial Operations |
| Dr. James Patrick Tursi M.D. | Executive Vice President of Global Research and Development |
| Frank B. Raciti | Vice President, Controller and Chief Accounting Officer |
| Cheryl Stouch | Senior Vice President of Information Technology and Chief Information Officer |
| Laure E. Park | Senior Vice President of Investor Relations and Corporate Affairs |
| Susan Williamson CPA | Senior Vice President and Chief Compliance Officer |
| Tracy Basso | Chief Human Resources Officer |